Myeloproliferative disorder clinical trials
28 active trials name this condition. Describe your situation to see which ones you may be eligible for.
Refine by biomarker
By location
- Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
- Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
- Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies
- Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
- Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
- Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
- A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
- Study of INCA036978 in Participants With Myeloproliferative Neoplasms
- Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant
- Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
- Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
- Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation
- Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies
- Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia
- Caris Chromoseq Data Collection
- Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- Registry of Older Patients With Cancer
- Considering alloHCT: Opportunities for Patient Reflection During Decision-Making Via Digital Stories
- GM-CSF With Post-Transplant Cyclophosphamide
- Assessment of Multi-Level Interventions to Improve Adherence to Oral Medications in Cancer Patients
- Phase 2 Study Of Imetelstat for Patient With Myelodysplastic/Myeloproliferative Neoplasms
- Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers
- Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN
- WELL-MPN: A Digital Lifestyle App for Patients With MPNs
- Pathogenesis of Hematologic Malignancies
- Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Myeloproliferative disorder” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.